Study Objective. To evaluate the safety and efficacy of valganciclovir 450 mg/day for 6
months for cytomegalovirus (CMV) prophylaxis in renal transplant recipients. Design. Single …

The availability of valganciclovir (VGCV) has significantly simplified the treatment of human
cytomegalovirus (HCMV) infection after solid-organ transplantation. We show that there was …

Background. The role of valganciclovir in the prevention of cytomegalovirus (CMV) disease
in high-risk seropositive transplant patients is not known. Methods. We prospectively …

Background. We conducted a trial of long-term ganciclovir prophylaxis for prevention of
primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with …

The precise impact of valganciclovir as preventive therapy for cytomegalovirus (CMV) in
solid organ transplant (SOT) recipients is not fully defined. Data from studies using …

Background. Without effective antiviral prophylaxis, cytomegalovirus (CMV) disease is a
common cause of morbidity and mortality after liver transplantation. In this randomized …

Prophylaxis reduces cytomegalovirus (CMV) disease, but is associated with increased costs
and risks for side effects, viral resistance and late onset CMV disease. Preemptive therapy …

Background: Solid organ transplantation (SOT) frequently is complicated by cytomegalovirus
(CMV) infections. Cidofovir (CDV) is active against CMV, including many ganciclovir (GCV) …

The efficacy of valganciclovir as preemptive therapy for the prevention of cytomegalovirus
(CMV) disease and its impact on indirect sequelae of CMV were assessed in recipient …

The use of postdetection antiviral treatment of cytomegalovirus (CMV) as a strategy to
prevent infection and disease in solid-organ transplant patients has not been evaluated by …